Panel Discussion: What Should Be Characterized at Drug Substance vs Drug Product Stage?
- Explore which attributes should be controlled before formulation versus reassessed in the final LNP product
- Debate how much characterization is enough at different stages of development without creating unnecessary analytical burden
- Benchmark industry approaches for defining CQAs, release strategies, and regulatory-ready analytical packages